This HTML5 document contains 38 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/drugbank/drug/DB08953/identifier/wikipedia/
n10http://bio2rdf.org/drugbank:
n7http://linked.opendata.cz/resource/drugbank/drug/DB08953/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB08953
rdf:type
n3:Drug
n3:description
Indalpine was one of the first selective serotonin reuptake inhibitors to reach the American market. It was initially marketed by Pharmuka. However, after the emergence of widespread concern regarding adverse effects caused by SSRIs, and reported hematological effects caused by Indalpine, it was abruptly withdrawn from the US market.
n3:generalReferences
# Marcin LR, Mattson RJ, Gao Q, Wu D, Molski TF, Mattson GK, Lodge NJ: Synthesis and hSERT activity of homotryptamine analogs. Part 6: [3+2] dipolar cycloaddition of 3-vinylindoles. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1027-30. doi: 10.1016/j.bmcl.2009.12.043. Epub 2009 Dec 16. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20034793 # Galbaud du Fort G: [Hematologic toxicity of antidepressive agents]. Encephale. 1988 Jul-Aug;14(4):307-18. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3058454
n3:group
withdrawn investigational
owl:sameAs
n10:DB08953
dcterms:title
Indalpine
adms:identifier
n6:Indalpine n7:DB08953
n3:synthesisReference
U.S. Patent 4,064,255.
n3:IUPAC-Name
n4:271B5F75-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5F7B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5F7A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5F77-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5F78-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5F79-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5F73-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5F71-363D-11E5-9242-09173F13E4C5 n4:271B5F74-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5F72-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5F81-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5F82-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5F7C-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5F7D-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5F7F-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5F7E-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5F80-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
63758-79-2
n3:Bioavailability
n4:271B5F87-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5F89-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5F8A-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5F8B-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5F86-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5F85-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5F88-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5F76-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5F83-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5F84-363D-11E5-9242-09173F13E4C5